公开(公告)号：US12187682B2

公开(公告)日：2025-01-07

申请号：US18337313

申请日：2023-06-19

Applicant: Vettore, LLC

Inventor： Kenneth Mark Parnell ,  John McCall

IPC: C07D231/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D401/06 ,  C07D405/12 ,  C07D409/04 ,  C07D417/04

Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

公开(公告)号：US11292767B2

公开(公告)日：2022-04-05

申请号：US16222949

申请日：2018-12-17

Applicant: Vettore, LLC

Inventor： Kenneth Mark Parnell ,  John McCall ,  Donna Romero

IPC: C07D231/14 ,  C07D231/56 ,  A61P35/00 ,  C07D207/24 ,  C07C59/01 ,  C07D205/02 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D213/12 ,  A61K45/06 ,  A61K31/415 ,  C07D403/06 ,  C07D405/06 ,  C07D405/14

Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

公开(公告)号：US10214492B2

公开(公告)日：2019-02-26

申请号：US15839539

申请日：2017-12-12

Applicant: Vettore, LLC

Inventor： Kenneth Mark Parnell ,  John McCall ,  Donna Romero

IPC: C07D231/14 ,  C07D231/56 ,  A61P35/00 ,  C07D207/24 ,  C07C59/01 ,  C07D205/02 ,  C07D405/14 ,  A61K31/415 ,  C07D403/06 ,  C07D405/06

Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

公开(公告)号：US20160362378A1

公开(公告)日：2016-12-15

申请号：US15180623

申请日：2016-06-13

Applicant: Vettore, LLC

Inventor： Kenneth Mark Parnell ,  John McCall

IPC: C07D231/12 ,  A61K31/415 ,  C07D417/04 ,  A61K31/427 ,  C07D405/12 ,  A61K31/4439 ,  C07D409/04 ,  A61K31/4155 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/06

CPC classification number: C07D231/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D401/06 ,  C07D405/12 ,  C07D409/04 ,  C07D417/04 ,  A61K2300/00

Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Abstract translation: 还提供了在人或动物受试者中抑制MCT4活性的方法。

公开(公告)号：US11155522B2

公开(公告)日：2021-10-26

申请号：US17030243

申请日：2020-09-23

Applicant: Vettore, LLC

Inventor： Kenneth Mark Parnell ,  John McCall

IPC: C07D231/12 ,  A61P35/00 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/06 ,  C07D405/12 ,  C07D409/04 ,  C07D417/04

Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

公开(公告)号：US11724989B2

公开(公告)日：2023-08-15

申请号：US17481660

申请日：2021-09-22

Applicant: Vettore, LLC

Inventor： Kenneth Mark Parnell ,  John McCall

IPC: C07D231/12 ,  A61P35/00 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/06 ,  C07D405/12 ,  C07D409/04 ,  C07D417/04

CPC classification number: C07D231/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D401/06 ,  C07D405/12 ,  C07D409/04 ,  C07D417/04 ,  A61K31/415 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00

Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I




and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

公开(公告)号：US10202350B2

公开(公告)日：2019-02-12

申请号：US15180623

申请日：2016-06-13

Applicant: Vettore, LLC

Inventor： Kenneth Mark Parnell ,  John McCall

IPC: C07D231/12 ,  A61K31/415 ,  C07D417/04 ,  A61K31/427 ,  C07D405/12 ,  A61K31/4439 ,  C07D409/04 ,  A61K31/4155 ,  A61K45/06 ,  C07D401/06 ,  A61K31/5377

Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.